Eric Poma

USPTO Granted Patents = 20 (Patent Applications = 34)

CIPO Patents = 4 (Patent Applications = 14)

EPO Patents = 14 (Patent Applications = 33)

Average Co-Inventor Count = 3.6

ph-index = 5

Forward Citations = 66(Granted Patents)

Company Filing History:

20 out of 26

Molecular Templates, Inc.

patents

2 out of 850

Millennium Pharmaceuticals Limited

patents

where one patent can have more than one assignee

Years Active: 2019-2024

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12180284 - Clinical methods for use of a PD-L1-binding molecule comprising a Shiga toxin effector (2024-12-31),

2. 12180262 - CD38-binding proteins comprising de-immunized Shiga toxin A subunit effectors (2024-12-31),

3. 12065469 - De-immunized Shiga toxin a subunit effector polypeptides for applications in mammals (2024-08-20),

4. 12037367 - MHC class I epitope delivering polypeptides (2024-07-16),

5. 11918649 - PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds (2024-03-05),

6. 11857628 - Shiga toxin A subunit effector polypeptides, Shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation (2024-01-02),

7. 11713347 - CD38-binding proteins comprising de-immunized Shiga toxin A subunit effectors (2023-08-01),

8. 11406692 - Cell-targeting molecules comprising de-immunized, Shiga toxin a subunit effectors and CD8+ t-cell epitopes (2022-08-09),

9. 11389542 - Shiga toxin a subunit effector polypeptides, Shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation (2022-07-19),

10. 11365223 - De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same (2022-06-21),

11. 11312751 - MHC class I epitope delivering polypeptides (2022-04-26),

12. 11248061 - Multivalent CD20-binding molecule comprising Shiga toxin A subunit effector polypeptides and enriched compositions thereof (2022-02-15),

13. 11225509 - HER2-targeting molecules comprising de-immunized, Shiga toxin A subunit scaffolds (2022-01-18),

14. 11142584 - CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same (2021-10-12),

15. 11136395 - PD-L1 -binding molecules comprising Shiga toxin A subunit scaffolds (2021-10-05),

Title: The Innovative Contributions of Eric Poma

Introduction

Eric Poma, located in New York, NY, is a distinguished inventor known for his significant contributions to the field of biotechnology. With a remarkable portfolio of 20 patents, his work primarily focuses on developing clinical methods and binding molecules that can potentially revolutionize cancer treatments.

Latest Patents

Among Eric's latest patents is the development of clinical methods for using a PD-L1-binding molecule comprising a Shiga toxin effector. This innovation involves PD-L1-binding molecules designed to selectively kill specific cells, including PD-L1 positive tumor cells and immune cells. It also aims at delivering cargos specifically to these cells, demonstrating potential as a therapeutic avenue for treating cancer, particularly non-small cell lung cancer and squamous cell carcinoma of the head and neck.

Additionally, he has introduced CD38-binding proteins that encompass de-immunized Shiga toxin A subunit effectors. These proteins are designed for cell-targeting through a CD38-binding region while retaining specific Shiga toxin functions, making them valuable in diagnosing and treating cancers and disorders that involve CD38-expressing cells, such as multiple myeloma.

Career Highlights

Eric Poma has made substantial contributions while working at notable companies such as Molecular Templates, Inc. and Millennium Pharmaceuticals Limited. His innovative spirit and dedication toward advancing biotechnology have led to his recognition as a pioneer in his field.

Collaborations

Throughout his career, Eric has collaborated with talented professionals including Erin Willert and Jack Higgins. These partnerships have fostered an environment of innovation, enabling the development of groundbreaking therapies and methodologies in cancer treatment.

Conclusion

In summary, Eric Poma's work is a testament to the impact that targeted innovations can have in the medical field, especially in combating cancer. With his extensive patent portfolio and collaborative efforts, he continues to pave the way for advancements that hold great promise for future therapies.

This text is generated by artificial intelligence and may not be accurate.